PDCD1 and cancer: This retrospective study, which covered the period September 2013–May 2018, encompassed fifteen Italian centers and a total of 751 patients with various types of cancer, predominantly NSCLC (65.5%), melanoma (21.2%) and renal cancer (12.5%), treated with PD-1 (pembrolizumab or nivolumab)-targeted immunotherapy (47).